Natural Biocon (543207)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at roughly 0.99 times book value, reducing the premium paid over stated net assets.
• Book value per share of ₹11.67 provides a potential asset cushion against the current market price.
• Balance sheet has not been wiped out despite the collapse in sales and negligible profitability.
• Small market cap of ₹31 Cr means even a modest operational recovery could have a material per-share impact.

Concerns

• Sales growth is -100% and latest quarterly sales are ₹0 Cr, indicating no active revenue generation.
• ROE is -1.35% and ROCE is 0.27%, showing negligible or negative returns on capital employed.
• Piotroski F-Score of 3/9 points to weak financial health and limited fundamental improvement.
• Promoter holding is not available, creating a lack of transparency for minority shareholders.

AI Analysis

At ₹11.56, Natural Biocon is a curious case. The market cap is ₹31 Cr, and the stated book value is ₹11.67 per share, so I am paying roughly a rupee for every rupee of net assets. On the surface, that appears to be a Graham-style asset play. But the business itself shows no life. The latest quarter sales are ₹0 Cr, sales growth is -100%, and net profit is -₹0 Cr. Earnings are zero, so the P/E denominator is absent. ROCE is 0.27% and ROE is -1.35%. In plain language, capital employed is producing almost nothing, and shareholders' equity is being eroded. This is not a franchise; there is no competitive moat, no pricing power, no growth. The Piotroski F-Score of 3 out of 9 reinforces my caution. It tells me financial health is weak. The 52-week range of ₹3.09 to ₹11.56 means the stock has quadrupled, but that appears to be speculative heat, not underlying earning power. With no dividend, no sales, and no promoter holding visible, I cannot value this as a going concern. The only possible value lies in the balance sheet. But book value is only the starting point for analysis, not the conclusion. I must know whether those assets are real, liquid, and honestly stated. If they are, there may be asset value. If not, the downside is meaningful. I would not buy hope. I would wait for a clear catalyst: resumption of operations, a restructuring, or a price well below net asset value. Until then, this remains a show-me story, not an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer